Cargando…
Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
Aberrant phosphorylation and overexpression of BCR-ABL fusion protein are responsible for the main pathogenesis in chronic myeloid leukemia (CML). Phosphorylated BCR-ABL Y177 recruits GRB2 adaptor and triggers leukemic RAS-MAPK and PI3K-AKT signals. In this study, we engineered a SPOA system to deph...
Autores principales: | Gao, Miao, Huang, Zheng-Lan, Tao, Kun, Xiao, Qing, Wang, Xin, Cao, Wei-Xi, Xu, Min, Hu, Jing, Feng, Wen-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356883/ https://www.ncbi.nlm.nih.gov/pubmed/27926512 http://dx.doi.org/10.18632/oncotarget.13754 |
Ejemplares similares
-
Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013) -
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
por: Zhu, Han-Qing, et al.
Publicado: (2019) -
Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
por: Li, Yajuan, et al.
Publicado: (2013) -
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022) -
Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)